| Budget Amount *help |
¥17,550,000 (Direct Cost: ¥13,500,000、Indirect Cost: ¥4,050,000)
Fiscal Year 2020: ¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2019: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2018: ¥9,230,000 (Direct Cost: ¥7,100,000、Indirect Cost: ¥2,130,000)
|
|---|
| Outline of Final Research Achievements |
Intentional enhancement of immune response of the host to induce a systemic abscopal effect is very attractive in oncology and represents an innovative next-generation therapeutic approach. The aim of this study was to establish the scientific basis for the development of a therapeutic strategy to expand the response of irradiation from local to systemic therapy using immune checkpoint inhibitors, focusing on tumor immunity, which has been attracting the greatest attention in recent years. Since the biomarker/specific neoantigen/optimal irradiation method was unknown, a prospective clinical study with SBRT was considered.
We thoroughly investigated the status of domestic and international research and established a cross-sectional cooperative system to administer PD-(L)1 antibody, though invasive procedures were delayed due to the impact of COVID-19 and other factors, which affected the execution of the study.
|
